We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · March 14, 2019

6-Month vs 12-Month Capecitabine as Adjuvant Chemotherapy for Patients With Stage III Colon Cancer

British Journal of Cancer

 

Additional Info

British Journal of Cancer
Phase III Randomised Trial Comparing 6 vs. 12-Month of Capecitabine as Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Final Results of the JFMC37-0801 Study
Br. J. Cancer 2019 Mar 05;[EPub Ahead of Print], N Tomita, K Kunieda, A Maeda, C Hamada, T Yamanaka, T Sato, K Yoshida, N Boku, R Nezu, S Yamaguchi, H Mishima, S Sadahiro, K Muro, M Ishiguro, J Sakamoto, S Saji, Y Maehara

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading